Medispend Resources
Beyond Disclosure – Building a Unified Transparency Workflow
Disclosure, anonymization, and transparency usually run as separate workstreams — different owners, different systems, different audit trails. That’s where risk hides, and the gap is widening as Patient Lay Summaries, EHDS, and new global disclosure mandates stack on top of what teams already manage. This session, first presented at Informa’s
AI & Scientific Exchange: What It Means for Medical Affairs
Beacon Webinar · On Demand · Recorded Thursday, September 24, 2026 How MSLs Are Using AI Search Today, and What’s Coming Next MSLs don’t work from the same handful of slides every day. Every KOL conversation is different, which means every interaction starts with a search for the right document,
Coaching & Feedback: The Manager Skill Set That Actually Moves the Needle
iCoach Webinar · On Demand · Recorded Tuesday, September 22, 2026 Coaching & Feedback: The Manager Skill Set That Actually Moves the Needle Most feedback conversations at work get avoided, or handled so poorly they backfire. That’s a costly gap: Gallup found manager quality drives up to 70% of the
How to Keep Feedback from Backfiring (And What to Do If It Does)
Even well-prepared feedback can go sideways, defensiveness, silence, tears, or pushback. This field-tested guide gives Life Sciences managers and coaches a system for delivering feedback that lands, whether it happens in the field, on video, or in writing. Every manager has had a coaching conversation go off the rails. You
A Beacon Buyer’s Guide
Choosing a Scientific Exchange Platform Scientific exchange is one of the highest-stakes relationships Medical Affairs owns. Get the platform wrong and the damage doesn’t stay contained. It shows up as poor MSL adoption, field conversations that never turn into strategic insight, and a Medical Affairs function that starts to look
Government Pricing Readiness Checklist
Government pricing compliance is one of the highest-stakes challenges in life sciences. Errors in Medicaid Best Price, AMP, or 340B calculations don’t stay contained. They compound into retroactive rebate exposure, regulatory scrutiny, and the kind of late-stage surprises that erode trust in your revenue numbers. For growing pharma organizations, the